阿加曲班在不同程度急性脑梗死患者中的应用效果  

Application effect of Argatroban in patients with different degrees of acute cerebral infarction

作　　者：刘微微 曹少雄 张寿全 LIU Weiwei;CAO Shaoxiong;ZHANG Shouquan(Department of Neurology,Heyuan People's Hospital,Guangdong Province,Heyuan517000,China;Department of Emergency,Heyuan People's Hospital,Guangdong Province,Heyuan517000,China)

机构地区：[1]广东省河源市人民医院神经内科,广东河源517000 [2]广东省河源市人民医院急诊科,广东河源517000

出　　处：《中国当代医药》2023年第4期102-104,112,共4页China Modern Medicine

基　　金：广东省河源市科技计划项目(河科社045)。

摘　　要：目的探讨阿加曲班在不同程度急性脑梗死患者中的应用效果。方法选取2018年6月至2021年12月河源市人民医院神经内科收治的180例急性脑梗死患者作为观察对象,依据美国国立卫生研究院量表(NIHSS)评分将其分为A组(NIHSS评分0~4分)、B组(NIHSS评分5~8分)、C组(进展性卒中),各60例患者,并依据随机数字表法分别将三组患者各分为亚组,每个亚组各30例患者。A2组、B2组、C2组患者均给予常规治疗,A1组、B1组、C1组患者均联合阿加曲班治疗。分别比较A1组和A2组、B1组与B2组、C1组和C2组患者的疗效及不良反应发生情况。结果A1组患者的治疗总有效率高于A2组,差异有统计学意义(P<0.05)。A1组和A2组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。B1组与B2组患者的治疗总有效率比较,差异无统计学意义(P>0.05)。B1组与B2组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。C1组的治疗总有效率高于C2组,差异有统计学意义(P<0.05)。C1组和C2组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论阿加曲班治疗轻度、进展性急性脑梗死的效果和安全性良好。Objective To explore the application effect of Argatroban in patients with different degrees of acute cerebral infarction.Methods A total of 180 patients with acute cerebral infarction who were admitted to the Department of Neurology,Heyuan People's Hospital from June 2018 to December 2021 were selected as observation objects.According to the National Institutes of Health stroke scale(NIHSS)score,the patients were divided into group A(NIHSS score 0-4 points),group B(NIHSS score 5-8 points)and group C(progressive stroke),with 60 patients each,and the three groups were divided into subgroups according to the random number table method,with 30 patients in each subgroup.All patients in group A2,B2 and C2 were given conventional treatment,and all patients in group A1,B1 and C1 were treated with Argatroban.The efficacy and occurrence of adverse reactions in groups A1 and A2,B1 and B2,C1 and C2 were compared,respectively.Results The total effective rate of group A1 was higher than that of group A2,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between group A1 and Group A2(P>0.05).There was no significant difference in the total effective rate between group B1 and B2(P>0.05).There was no significant difference in the total incidence of adverse reactions between group B1 and B2(P>0.05).The total effective rate of group C1 was higher than that of group C2,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between group C1 and C2(P>0.05).Conclusion Argatroban is effective and safe in the treatment of mild and progressive acute cerebral infarction.

关 键 词：阿加曲班 急性脑梗死 疗效 不良反应 

分 类 号：R743.33[医药卫生—神经病学与精神病学]